期刊文献+

酪丝缬肽的结构修饰及其稳定性和安全性的初步评价

Structural Modification of Tyroservatide and the Prelimary Evaluation of Their Stability and Safety
下载PDF
导出
摘要 通过固相多肽法成功合成了酪丝缬肽(YSV)以及其结构修饰物(Z-GP-YSV-NH2),总收率分别为45.3%和52.3%。分别研究了YSV和Z-GP-YSV-NH2在PBS缓冲液、DMEM培养基和大鼠血浆中的稳定性,发现两者在PBS和DMEM中都很稳定,但YSV在大鼠血浆中温浴2 h后基本降解完全;而Z-GP-YSV-NH2温浴12h后只降解67%。还评价了YSV和Z-GP-YSV-NH2对人胚肾细胞293的细胞毒性,发现两者的细胞毒性都很低。当剂量为200μg/mL时,其增殖抑制率分别为20%和10.3%。 Tyroservatide (YSV) and its structural modification (Z-GP-YSV-NH2) were successfully synthesized by solidphase peptide synthesis. The overall yields were 45.3% and 52.3% respectively. The stabilities of YSY and Z-GP-YSV-NH2 in PBS buffer, DMEM culture and rat blood plasma were also investigated in this study. It was found that both YSV and Z-GP-YSV-NH2 were stable in either PBS or DMEM medium. However, YSV was completely degraded after bathing in rat blood plasma for 2 h; while only 67% of Z-GP-YSV-NH2 was degraded after 12-hours bath. In current paper, the cytotoxicities of YSV and Z-GP-YSV-NH2 to human renal cell 293 were also evaluated. It was displayed that the cytotoxicities of both compounds were very low, in which the growth inhibition rate were 20% and 10.3% respectively when the dosages were 200 μg/mL.
出处 《中山大学学报(自然科学版)》 CAS CSCD 北大核心 2013年第2期101-105,共5页 Acta Scientiarum Naturalium Universitatis Sunyatseni
基金 国家自然科学基金资助项目(81172982 30973565)
关键词 酪丝缬肽 结构修饰 抗肿瘤肽 tyroservatide structural modification antitumor peptides
  • 相关文献

参考文献10

  • 1CHEN Y, HU L Q. Design of anticancer prodrugs for re- ductive activation [ J ]. Medicinal Research Reviews, 2009, 29 ( 1 ) : 29 - 64.
  • 2郑杰.做好靶向病理诊断 夯实肿瘤靶向治疗的基础[J].中华病理学杂志,2007,36(7):433-434. 被引量:7
  • 3HU L Q. Prodrugs: Effective solutions for solubility per- meability and targeting challenges [ J ]. Drugs, 2004, 7 (8) : 736 - 742.
  • 4颜琪,郭静,冯聪敏,赵宝华.靶向抗肿瘤药物研究进展[J].生物技术通报,2012,28(8):40-45. 被引量:5
  • 5方瑞,杜军,陈宏远,蔡绍晖.成纤维细胞激活蛋白α与肿瘤的靶向治疗[J].中国生物工程杂志,2008,28(3):100-105. 被引量:8
  • 6AERTGEERTS K, LEVIN I, SHI L, et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha [ J ]. J Biol Chem, 2005, 280 : 19441 - 19444.
  • 7HUANG S, FANG R, XU J, et al. Evaluation of the tumor targeting of a FAPct-based doxorubiein prodrug [J]. J Drug Targeting, 2011, 19(7) : 487 -496.
  • 8SUAREZ-JIMENEZ G M, BURGOS-HERNANDEZ A, EZQUERRA-BRAUER J M. Bioactive peptides and dep- sipeptides with anticancer potential: Sources from marine animals[J]. Mar Drugs, 2012, 10:963 -986.
  • 9贾晋斌,王文权,林刚.新型抗癌药酪丝亮肽和酪丝缬肽的研究进展[J].中国新药与临床杂志,2009,28(6):401-404. 被引量:5
  • 10DING W, ZHAblG J, YAO Z, et al. The synthesis, distribution, and anti-hepatic cancer activity of YSL [J]. Bioorg Med Chem, 2004, 12(18) : 4989 -4994.

二级参考文献59

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部